Navigation Links
Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
Date:11/3/2008

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its third quarter financial results on Thursday, November 6, 2008 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.

The discussion is planned for a live webcast and can be accessed at http://www.oncothyreon.com under the "News & Events" section. It is expected that the archive of the webcast will be available approximately one hour after completion of the discussion and will be posted on the Oncothyreon website for 30 days.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon to present at BIO Investor Forum 2008
2. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
3. Oncothyreon announces prioritization plan for development programs
4. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
5. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
6. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
7. Oncothyreon to receive milestone payment
8. Oncothyreon Reports First Quarter 2008 Financial Results
9. Oncothyreon files investigational new drug application for PX-866 oncology compound
10. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
Breaking Biology News(10 mins):